You are here

Our science / Clinical Trials / Find a Trial / NCT00422461

A Dose Finding Study Of PF-00489791 In Patients With Mild To Moderate High Blood Pressure

Back to Search Print Save as PDF Bookmark Trial

NCT00422461

Last updated on August 9, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Los Angeles, California, 90057 United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Hypertension
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-70 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Males and/or Females of non-childbearing potential between 18 and 70 years of age

2. History of mild to moderate hypertension

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

1. Type 1 or 2 diabetes on prescribed medications

2. Secondary, severe, or malignant hypertension

3. History of a significant cardiovascular event within the last 12 months of enrollment

NCT00422461
Pfizer
Completed
A Dose Finding Study Of PF-00489791 In Patients With Mild To Moderate High Blood Pressure

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Familial Persistent Pulmonary Hypertension
A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn
NCT01720524
All Genders
0+
Years
Multiple Sites
Pulmonary Arterial Hypertension
Sildenafil Therapy For Subjects Who Derive Clinical Benefit From Continued Treatment With Sildenafil
NCT01897740
All Genders
10+
Years
Moscow,
Pulmonary Arterial Hypertension
Open Label Access Study Of Sildenafil In Adult Patients With Pulmonary Arterial Hypertension Completing A1481244 Study
NCT00878943
All Genders
18+
Years
Multiple Sites
Glaucoma, Ocular Hypertension
Efficacy and Tolerability of Xalatan in Patients
NCT00950690
All Genders
18+
Years
Multiple Sites
A Dose Finding Study Of PF-00489791 In Patients With Mild To Moderate High Blood Pressure
A Phase 2, Randomized, Placebo-Controlled, Dose-Ranging Study Of PF-00489791 In Subjects With Stage 1 And 2 Essential Hypertension Using Ambulatory Blood Pressure Monitoring (ABPM)
The purpose of this study is to evaluate the safety and blood pressure lowering effect of different doses of PF-00489791 in patients with mild to moderate high blood pressure
Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Hypertension
  • Drug: PF-00489791
    PF-00489791 4 mg, oral, tablets, once daily, for 28 days
  • Drug: PF-00489791
    PF-00489791 10 mg, oral, tablets, once daily, for 28 days
  • Drug: PF-00489791
    PF-00489791 20 mg titrated to 40 mg, oral, tablets, once daily, for 28 days
  • Drug: placebo
    placebo, oral, tablets, once daily, for 28 days
  • Experimental: PF-00489791 4 mg
    Intervention: Drug: PF-00489791
  • Experimental: PF-00489791 10 mg
    Intervention: Drug: PF-00489791
  • Experimental: PF-00489791 20 mg titrated to 40 mg
    Intervention: Drug: PF-00489791
  • Placebo Comparator: Placebo
    Intervention: Drug: placebo
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
140
January 2008
January 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Males and/or Females of non-childbearing potential between 18 and 70 years of age
  2. History of mild to moderate hypertension

Exclusion Criteria:

  1. Type 1 or 2 diabetes on prescribed medications
  2. Secondary, severe, or malignant hypertension
  3. History of a significant cardiovascular event within the last 12 months of enrollment
Sexes Eligible for Study: All
18 Years to 70 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00422461
A7331007
No
Not Provided
Not Provided
Director, Clinical Trial Disclosure Group, Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
October 2009

ICMJE     Data element required by the

International Committee of Medical Journal Editors and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now